LANREOTIDE ACETATE
( DrugBank: Lanreotide, Acetate / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials | 
|---|---|---|
| 67 | Polycystic kidney disease | 1 | 
| 73 | TSH-secreting pituitary adenoma | 1 | 
| ID | Disease name (Link within this page) | Number of trials | 
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 | 
| 298 | Hereditary pancreatitis | 1 | 
67. Polycystic kidney disease
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
73. TSH-secreting pituitary adenoma
Clinical trial : 1 / Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|